ReviewEuropean respiratory review : an official journal of the European Respiratory Society2021
Sex and gender in pulmonary arterial hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension.The Cochrane database of systematic reviews · 2025Pooled it
- Pregnancy conditions and outcomes of Chinese women with mild, moderate and severe pulmonary arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Pooled it
- Effectiveness and safety of inspiratory muscle training in patients with pulmonary hypertension: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2022Pooled it
- Burden dynamics of pulmonary arterial hypertension in China and the G20 aggregate: a comparative analysis based on the global burden of disease study 2023.Annals of medicine · 2026Article
- Review
- The Clinical and Economic Burden of Pulmonary Arterial Hypertension in Israel, 2014-2022: A Retrospective Analysis of Healthcare Costs and Utilization.Pulmonary circulation · 2026Article
- Right Heart Diastology, Where Are We Now?Circulation research · 2026Review
- National Patterns of Pulmonary Hypertension Mortality in the United States, 2010 to 2024.The American journal of cardiology · 2026Article
- Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry.Respiration; international review of thoracic diseases · 2026Article
- Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries.Life (Basel, Switzerland) · 2026Article
- Why Men Fare Worse: Understanding Gender Disparities in Systemic Sclerosis-Associated Pulmonary Hypertension.Clinical Medicine Insights. Cardiology · 2026Article
- SARS-CoV-2 infection and two-year longitudinal clinical trajectory in pulmonary hypertension: a single-center retrospective exploratory cohort study.Frontiers in public health · 2026Article
- Successful Pregnancy in Chronic Obstructive Pulmonary Hypertension Secondary to Pulmonary and Cardiac Hydatid Cysts: A Case Report.Research in heart yield and translational medicine · 2026Article
- Sex-Specific Interventricular Septum Mechanics in Pulmonary Arterial Hypertension.Annals of biomedical engineering · 2026Article
- Inequity in imaging: Why it matters? A statement from the Equity, Diversity and Inclusion Subcommittee of the European Society of Radiology.Insights into imaging · 2025Article
- Combination of Orai1 inhibitor CM5480 with specific therapy mitigates pulmonary hypertension and its cardiac dysfunction.JCI insight · 2025Article
- Examining the Disproportionate Burden of Microvascular Disease in Women.Current atherosclerosis reports · 2025Review
- Right Ventricular Stiffening and Anisotropy Alterations in Pulmonary Hypertension: Mechanisms and Relations to Right Heart Failure.Journal of the American Heart Association · 2025Article
- Connexin 43 Affects Pulmonary Artery Reactivity via Changes in Nitric Oxide Production and Influences Proliferative and Migratory Responses in Mouse Pulmonary Artery Fibroblasts.International journal of molecular sciences · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease characterised by pulmonary vascular remodelling and elevated pulmonary pressure, which eventually leads to right heart failure and death. Registries worldwide have noted a female predominance of the disease, spurring particular interest in hormonal involvement in the disease pathobiology. Several experimental models have shown both protective and deleterious effects of oestrogens, suggesting that complex mechanisms participate in PAH pathogenesis. In fact, oestrogen metabolites as well as receptors and enzymes implicated in oestrogen signalling pathways and associated conditions such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.